Key safety considerations include: Infection risk : Any injection carries risk of infection if proper aseptic technique is not followed Allergic reactions : Multiple ingredients increase the potential for hypersensitivity Undiagnosed conditions : Self-administration or private clinic use may delay diagnosis of underlying medical conditions Pregnancy and breastfeeding : Safety data for lipotropic formulations in pregnancy is lacking Call 999 immediately if you experience signs of anaphylaxis (difficulty breathing, facial/tongue swelling, collapse) after an injection
Your results are the direct effect of new cell growth
Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors, giving it a broader metabolic mechanism than single- or dual-pathway therapies
S., Tsisanova E., Kelly E., Henderson G., et al
A study in the Journal of Clinical Endocrinology and Metabolism (online, Feb